Tango Therapeutics: Nextech reports 7.27M shares (5.1%)

Tango Therapeutics, Inc. Schedule 13G/A reports that Nextech Crossover I SCSp and related reporting persons beneficially own 7,266,081 shares of common stock as of March 31, 2026.

Rhea-AI Filing Summary

Tango Therapeutics, Inc. Schedule 13G/A reports that Nextech Crossover I SCSp and related reporting persons beneficially own 7,266,081 shares of common stock as of March 31, 2026. The filing states this represents 5.1% of the issuer's outstanding shares, based on 142,688,851 shares outstanding as of February 26, 2026. The cover rows show that Nextech Crossover I SCSp directly holds the shares, Nextech Crossover I GP S.a. r.l. is the general partner, and Ian Charoub, Costas Constantinides and Rocco Sgobbo have the power to direct voting and disposition of those securities. The Reporting Persons expressly disclaim status as a 'group.'

Insights

Corporate Governance Analyst

Disclosure clarifies ownership and control of a 5.1% stake.

The filing documents that 7,266,081 shares are held by Nextech Crossover I SCSp with voting and dispositive power exercisable via the GP and named managers as of March 31, 2026. The percentage uses the issuer's stated outstanding share count as of February 26, 2026.

Because the Reporting Persons disclaim being a "group," governance implications remain tied to the GP/manager structure. Subsequent filings could show changes; timing and cash‑flow treatment are not specified in the excerpt.

Investor Relations Specialist

Routine beneficial‑ownership amendment, useful for cap table transparency.

The amendment updates beneficial‑ownership rows and confirms who holds sole voting/dispositive power over the disclosed shares. Signatures dated May 15, 2026 complete the amendment.

This is a disclosure event rather than a transaction; it documents existing holdings and governance allocation rather than reporting an acquisition or disposition.

Key Figures

Shares beneficially owned: 7,266,081 shares Percent of class: 5.1% Shares outstanding (base): 142,688,851 shares +1 more

4 metrics

Shares beneficially owned 7,266,081 shares Beneficial ownership as of March 31, 2026

Percent of class 5.1% Based on 142,688,851 shares outstanding as of February 26, 2026

Shares outstanding (base) 142,688,851 shares Outstanding shares as reported in Form 10‑K filed March 5, 2026 (as of February 26, 2026)

Filing signature date May 15, 2026 Amendment signatures dated May 15, 2026

Key Terms

beneficially owned, sole dispositive power, Schedule 13G/A, general partner

4 terms

beneficially owned regulatory

"Row 9 of each Reporting Person's cover page to this sets forth the aggregate number of shares of common stock beneficially owned"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole dispositive power regulatory

"Row 7 of each Reporting Person's cover page ... sets forth the sole power to dispose or to direct the disposition"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Schedule 13G/A regulatory

"Item 1. (a) Name of issuer: Tango Therapeutics, Inc. ... Schedule 13G/A"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

general partner financial

"Nextech Crossover GP serves as the sole general partner of Nextech Crossover LP"

A general partner is the person or firm that runs an investment partnership and legally represents it — they make the day-to-day decisions, choose which assets to buy or sell, and are responsible for the partnership’s obligations. Investors care because the general partner’s judgment, risk-taking and fee and profit-sharing arrangements determine both the potential returns and the level of exposure to losses; think of the GP as the ship’s captain whose skill and honesty shape the voyage’s outcome.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake does Nextech Crossover report in Tango Therapeutics (TNGX)?

The filing states 7,266,081 shares are beneficially owned by Nextech Crossover I SCSp, representing 5.1% of common stock based on 142,688,851 shares outstanding as of February 26, 2026.

As of what date are the 7,266,081 shares reported?

The Schedule 13G/A shows the aggregate ownership number as of March 31, 2026. The outstanding‑share base used for the percentage is dated February 26, 2026.

Who has voting and disposition power over these shares?

Nextech Crossover I SCSp directly holds the shares; Nextech Crossover I GP S.a. r.l. is its general partner, and managers Ian Charoub, Costas Constantinides and Rocco Sgobbo have power to direct voting and disposition.

Does the filing say the reporting persons form a group?

The filing expressly states that the Reporting Persons "expressly disclaim status as a 'group'", indicating they do not assert group status for Section 13 purposes in this amendment.

When was the amendment signed?

Signatures on the amendment are dated May 15, 2026, which completes the filing's executed certification of the reported ownership information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 04:23 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Tango Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

87583X109

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

Nextech Crossover I GP S.a. r.l.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,266,081.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,266,081.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,266,081.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

Nextech Crossover I SCSp

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

LUXEMBOURG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 7,266,081.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 7,266,081.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,266,081.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

Ian Charoub

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWEDEN

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,266,081.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,266,081.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,266,081.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

Costas Constantinides

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CYPRUS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,266,081.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,266,081.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,266,081.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 87583X109

1

Names of Reporting Persons

Rocco Sgobbo

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 7,266,081.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 7,266,081.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

7,266,081.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tango Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 201 Brookline Ave., Suite 901, Boston, MA, 02215.
Item 2.
(a)	Name of person filing: The names of the persons filing this report (collectively, the 'Reporting Persons') are: Nextech Crossover I SCSp ('Nextech Crossover LP') Nextech Crossover I GP S.a r.l. ('Nextech Crossover GP') Ian Charoub ('Charoub') Costas Constantinides ('Constantinides') Rocco Sgobbo ('Sgobbo') The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G.
(b)	Address or principal business office or, if none, residence: Bahnhofstrasse 18 Zurich, Switzerland 8001
(c)	Citizenship: Nextech Crossover LP Luxembourg Nextech Crossover GP Luxembourg Charoub Sweden Constantinides Cyprus Sgobbo Switzerland
(d)	Title of class of securities: Common Stock, $0.001 par value per share
(e)	CUSIP No.: 87583X109
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. Nextech Crossover LP directly holds 7,266,081 shares of common stock. Nextech Crossover GP serves as the sole general partner of Nextech Crossover LP and Charoub, Constantinides and Sgobbo are members of the board of managers of Nextech Crossover GP. Each of Nextech Crossover GP, Charoub, Constantinides and Sgobbo possesses power to direct the voting and disposition of the securities held by Nextech Crossover LP.
(b)	Percent of class: Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 142,688,851 shares of common stock outstanding as of February 26, 2026, as reported in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 5, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
	(ii) Shared power to vote or to direct the vote: Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
	(iii) Sole power to dispose or to direct the disposition of: Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
	(iv) Shared power to dispose or to direct the disposition of: Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nextech Crossover I GP S.a. r.l.

Signature:	/s/ Ian Charoub
Name/Title:	By Ian Charoub, Manager
Date:	05/15/2026

Signature:	/s/ Costas Constantinides
Name/Title:	By Costas Constantinides, Manager
Date:	05/15/2026

Nextech Crossover I SCSp

Signature:	/s/ Ian Charoub
Name/Title:	By Nextech Crossover I GP S.a r.l., its General Partner, By Ian Charoub, Manager
Date:	05/15/2026

Signature:	/s/ Costas Constantinides
Name/Title:	By Nextech Crossover I GP S.a r.l., its General Partner, By Costas Constantinides, Manager
Date:	05/15/2026

Ian Charoub

Signature:	/s/ Ian Charoub
Name/Title:	Ian Charoub
Date:	05/15/2026

Costas Constantinides

Signature:	/s/ Costas Constantinides
Name/Title:	Costas Constantinides
Date:	05/15/2026

Rocco Sgobbo

Signature:	/s/ Rocco Sgobbo
Name/Title:	Rocco Sgobbo
Date:	05/15/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to the Schedule 13G filed by the Reporting Persons with the SEC on August 21, 2023).